Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Cancer

Deoxycytidine kinase (DCK)

Mouse and in vitro studies identified DCK inhibitors that could help treat cancer. DCK is associated with cancer cell growth and chemotherapy resistance. High throughput screening, SAR studies and cell-based assays identified small molecules that inhibit DCK with nanomolar IC50 values. In a mouse xenograft model of human leukemia, the lead inhibitor decreased DCK activity in tumors compared with vehicle. Next steps include identifying a lead clinical candidate and carrying out IND-enabling studies.

SciBX 6(36); doi:10.1038/scibx.2013.990
Published online Sept. 19, 2013

Patent application filed; licensing details available from the University of California, Los Angeles Office of Intellectual Property

Murphy, J.M. et al. J. Med. Chem.; published online Aug. 15, 2013;
doi:10.1021/jm400457y
Contact: Caius G. Radu, University of California, Los Angeles, Calif.
e-mail:

cradu@mednet.ucla.edu
Contact: Arnon Lavie, University of Illinois at Chicago, Chicago, Ill.
e-mail:

lavie@uic.edu